Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

or other indications by other companies or new pharmaceuticals and technological advances to treat the conditions addressed by Cinryze,  Buccolam and Plenadren;
  • changes in prescribing or procedural practices of physicians, including off-label prescribing of products competitive with Cinryze, Buccolam and Plenadren;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Cinryze and our other products in order to meet demand for each product;
  • our ability to receive regulatory approval for the use of Cinryze for additional indications and routes of administration and in additional territories in the timeframes we anticipate or at all;
  • the impact of healthcare reform legislation in the United States;
  • actions by the FDA and EMA or other government regulatory agencies;
  • the timing and results of anticipated events in our clinical development programs including studies with Cinryze subcutaneous formulations, Cinryze for antibody mediated rejection, and maribavir for treatment of CMV infections in transplant recipients;
  • whether we pursue regulatory approval of Plenadren in the United States; and
  • the timing and nature of potential business development activities related to our efforts to expand our current portfolio through in-licensing or other means of acquiring products in clinical development or marketed products and our efforts to find a partner for VP20621.
  • There can be no assurance that we will conduct additional studies or that we will be successful in gaining regulatory approval of Cinryze for additional indications, routes of administration or in additional territories.  The entry of competing generic products following FDA approval in April 2012 has and will continue to significantly affect our sales of Vancocin and our financial performance.  Biologics such as Cinryze require processing steps
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
    (Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
    (Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
    (Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
    Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
    ... Oct. 1 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... preclinical results for its CYT387 JAK1/JAK2 inhibitor program ... and selectivity profile which may provide significant clinical ... Phase I/II clinical study at Mayo Clinic in ...
    ... CITY, Oct. 1 /PRNewswire-FirstCall/ - Medicago U.S.A. Inc., ... MDG), a biotechnology company focused on developing highly ... technologies and Virus-Like Particles (VLPs), today announced that ... (D-NC) and U.S. Congressman David Price (D-NC), are ...
    ... (OTC Bulletin Board: BHRT ) a company ... cell therapies for the treatment of cardiovascular diseases, announced ... Seaside National Bank and Trust for a $980,000 loan ... with Bank of America. The loan is subject to ...
    Cached Biology Technology:YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 2YM Biosciences To Present Poster On CYT387 At The European School Of Haematology International Conference 3Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 2Medicago holds official groundbreaking ceremony for its U.S. commercial grade vaccine facility 3Bioheart, Inc. Announces Loan to be Assumed by Seaside 2Bioheart, Inc. Announces Loan to be Assumed by Seaside 3
    (Date:12/17/2014)... , Dec. 15, 2014 Research and ... the addition of the "Samsung Galaxy S5 ... report to their offering. ... a totally different sensing technology than the iPhone ... fingerprint sensor in its product. The ...
    (Date:12/17/2014)... 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ... robust – with the clinical data to back it ...
    (Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
    Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... pleasantly salty without adding more salt? Change the bread,s texture ... ACS, Journal of Agricultural and Food Chemistry that ... perceive bread as having saltier taste. The process could become ... risk factor for high blood pressure and heart disease. ...
    ... Every day, the human body produces new cells to regenerate ... this happens, the cells make copies of their DNA that ... process of copying the DNA, also called replication, is very ... DNA that are associated with malignant transformation or ageing. ...
    ... , Nov. 19, 2013 Dynasil Corporation of ... its contract research subsidiary, RMD Inc., has received four grants ... Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) ... continues to be on the cutting edge of new technologies," ...
    Cached Biology News:Spanish scientists identify a new ancestral enzyme that facilitates DNA repair 2Dynasil's RMD Subsidiary Awarded $4 Million in Technology Development Grants by U.S. Department of Energy 2Dynasil's RMD Subsidiary Awarded $4 Million in Technology Development Grants by U.S. Department of Energy 3
    Human RUNX2/CBFA1 MAb (Clone 232902)...
    Lipid-rich bovine serum albumin for cell culture (1). It is chromatographically purified and has an IgG content 0.1% (w/w)....
    normal rat IgM AF647...
    GlutaMAX-I Supplement...
    Biology Products: